Center for Intervention Development and Applied Research

干预开发和应用研究中心

• 批准号: 7812750
• 负责人: William T. Carpenter
• 金额: $ 9.17万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7812750
• 关键词: Address; Affect; Affective; Amendment; Amphetamines; Animal Model; Animals; Applied Research; Behavioral; Cholinergic Agents; Cholinergic Receptors; Clinical; Clinical Research; Cognitive; Data; Disease; Emotional; Equipment; Evaluation; Eye; Face; Family member; Fostering; Funding; Goals; Grant; Human; Impairment; Knowledge; Link; Maryland; Mental disorders; Mind; Modeling; Neurobehavioral Manifestations; Neurosciences Research; Nicotinic Receptors; Oxytocin; Patients; Rattus; Reading; Receptor Activation; Recovery; Research; Rodent; Schizophrenia; Signal Transduction; Social Conditions; Social Functioning; Stress; Symptoms; Testing; Therapeutic; Translating; Translational Research; Ultrasonics; conditioning; effective therapy; graduate student; improved; innovation; male; novel; novel therapeutic intervention; novel therapeutics; offspring; pre-clinical; prenatal stress; research study; response; social; social communication; therapy development; translational neuroscience; vocalization

DESCRIPTION (provided by applicant): This request for supplemental funding under the Recovery Act Limited Competition for Revision Applications (NOT-OD-09-058) for grant PSO MH082999-01 addresses the topic of Translational Science: Innovative Targets and Models for Developing Treatments for Mental Disorders. This supplement has three primary purposes. First, funds will be requested to retain an outstanding graduate student whose funding is ending. Second, to enable the purchase of a new piece of equipment to enhance our ability to perform translational neuroscience research and third, to adapt a research approach from human studies to studies in a preclinical animal model of schizophrenia and to evaluate a novel therapeutic approach for alleviating social impairments of schizophrenia using this unique translational strategy. Specifically, this amendment focuses on expanding the basic neuroscience research being performed under Project 1 and Core 3 of the Maryland Psychiatric Research Center for Intervention Development and Applied Research (CIDAR). Recent studies have shown that patients with schizophrenia are impaired in their ability to recognize and respond to facial affect displays are revealed in the Reading the Mind in the Eyes task. One of the goals of the CIDAR is to examine oxytocin's ability to improve this ability in patients with schizophrenia and their family members. Ultrasonic vocalizations are responsible for transmitting emotional information between rodents. The new studies being proposed in this Competitive Revision will evaluate whether animals exposed to prenatal stress, which models schizophrenia, have deficits in emitting ultrasonic vocalizations or responding to vocalizations that are related to positive affective states or negative affective states, similar to Reading the Mind in the Eyes task. In addition, we will evaluate the effect of oxytocin in our animal model of schizophrenia and determine whether it improves the animals ability to recognize and respond to vocalizations reflecting affective states. These studies will inform the clinical studies being performed in the CIDAR and facilitate novel treatment development for schizophrenia

描述（由申请人提供）：根据《恢复法有限竞争修订申请》(NOT-OD-09-058) 申请补充资金，授予 PSO MH082999-01，其主题是转化科学：开发精神障碍治疗方法的创新目标和模型。该补充品有三个主要目的。首先，将请求资金来保留资助即将结束的优秀研究生。其次，能够购买新设备，以增强我们进行转化神经科学研究的能力；第三，将研究方法从人体研究调整为精神分裂症临床前动物模型的研究，并评估使用这种独特的转化策略减轻精神分裂症社会障碍的新治疗方法。具体来说，该修正案的重点是扩大马里兰州精神病学干预发展和应用研究中心 (CIDAR) 项目 1 和核心 3 下正在进行的基础神经科学研究。最近的研究表明，精神分裂症患者识别和响应面部情感表现的能力受到损害，这一点在“从眼睛中读懂心灵”任务中得到揭示。 CIDAR 的目标之一是检查催产素是否有能力提高精神分裂症患者及其家人的这种能力。超声波发声负责在啮齿动物之间传递情感信息。本竞争性修订版中提出的新研究将评估暴露于产前压力（模拟精神分裂症）的动物在发出超声波发声或对与积极情感状态或消极情感状态相关的发声做出反应方面是否存在缺陷，类似于“从眼睛里读心”任务。此外，我们将评估催产素在我们的精神分裂症动物模型中的作用，并确定它是否可以提高动物识别和响应反映情感状态的发声的能力。这些研究将为 CIDAR 正在进行的临床研究提供信息，并促进精神分裂症新疗法的开发